Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 10; 35(10):2854-2861.

View in: PubMed

subject areas

Adenine
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Atrial Fibrillation
Bendamustine Hydrochloride
Female
Follow-Up Studies
Humans
Hypertension
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Piperidines
Prognosis
Rituximab
Survival Rate

authors with profiles

Richard A. Larson